PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM

Slides:



Advertisements
Similar presentations
Implementing NICE guidance
Advertisements

LHD Logo Venous Thromboembolism Reducing the Risk DATE.
2012 CHEST Guideline Update VTE prophylaxis, DVT treatment, and Atrial Fibrillation LT Tabatha Welker, PharmD Pharmacy Resident, PHS Claremore Indian Hospital.
IN THE NAME OF GOD. Prevention of Venous Thromboembolism Dr.Shirali.
Deep Vein Thrombosis and Pulmonary Embolism prophylaxis in Asian general surgical patients: is it necessary?  AMY KOK Caritas Medical Centre.
VTE in abdominal-pelvic surgery patients
+ Deep Vein Thrombosis Common, Preventable, and potentially Fatal.
Antithrombotic Therapy for Venous Thromboembolic Diseases
DVT PROPHYLAXIS SUNDIP PATEL 7 / 15 / BACKGROUND Deep Vein Thrombosis is a common, yet preventable peri-operative complication Highest risk in critical.
Venous Thromboembolism Prevention August Venous Thromboembloism Prevention 2 Expected Practice  Assess all patients upon admission to the ICU for.
Venous Thromboembolism in the Surgical Patient: Prophylaxis and Treatment Pamela Hebbard August 11, 2005.
Venous Thromboembolism Prophylaxis and Management in the Medical Patient at Sisters of Charity Hospital Jeffrey Parker, DO Dr. Nashat Rabadi, MD Sisters.
Prophylaxis of Venous Thromboembolism
Venous thromboembolism –
Venous Thromboembolism (VTE) Prophylaxis Policy Mary-Anne Davies Patient Safety Specialist Accreditation Coordinator.
Deep Vein Thrombosis (DVT)
Perioperative Medicine Beyond Cardiac Clearance Pamela Pride MD July 31, 2012 MUSC.
Beverley Hunt Simon Noble Hospital Acquired Venous Thromboembolism.
RecommendationsRecommendations Risk Recommendation Ambulation (all pts) IPC/GCS or, UFH 5000 SQ q 12 hrs or, Enoxaparin 40mg SQ daily IPC/GCS or, UFH 5000.
DVT Prophylaxis in Medical Patients Rog Kyle, MD MUSC 6/5/12.
Venous ThromboEmbolism
CHEST-2012: High Points and Pearls Alan Brush, MD, FACP Chief, Anticoagulation Management Service Harvard Vanguard Medical Associates.
Venous thromboembolism: how long to treat?
DVT/VTE Nursing Protocol (Deep Vein Thrombosis) (Venous Thromboembolism) Presented by Maribeth Desiongco MA, RN-BC 2008.
LIFEBLOOD THE Thrombosis CHARITY Venous thromboembolism – Treatment and secondary prevention Ulcus cruris Chronic PE PE DVT Post-thrombotic syndrome Death.
Medical Patients – VTE Prevention Dale W. Bratzler, DO, MPH Professor and Associate Dean, College of Public Health Professor of Medicine, College of Medicine.
DVT Prophylaxis in Orthopedic Patients Rogers Kyle 11/27/12.
Peri-operative management of anticoagulation Marc Carrier MD, MSc FRCPC Assistant Professor, University of Ottawa Associate Scientist, Ottawa Health Research.
Total Joint Replacement
Thromboprophylaxis in Pregnancy and the Puerperium
Prevention Of Venous Thromboembolism In The Cancer Surgical Patient A K Kakkar Barts and the London School of Medicine and Thrombosis Research Institute,
Perioperative Medicine Beyond Cardiac Clearance Pamela Pride MD July 31, 2012 MUSC.
1 VTE Protocol Presented by: Selina Baskins, RN Quality Coordinator.
Venous Thromboembolism
7th ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines.
Prevention of Venous Thromboembolism 8 th ACCP Guidelines Chest 2008.
The Role of Thromboprophylaxis in Elective Spinal Surgery The Role of Thromboprophylaxis in Elective Spinal Surgery VA Elwell, N Koo Ng, D Horner & D Peterson.
Preoperative Management of Hypoxic Patients
Preventing Hospital Acquired Thrombosis Simon Noble Peggy Edwards.
H.R. Buller, G. Agnelli Presented at the XXIst Congress of International Society on Thrombosis and Haemostasis (ISTH) 2007 Meeting, July 6-12th in Geneva,
VTE Venous ThromboEmbolism. VTE – aims of this module To define the terms associated with VTE and offer maximum care to treat patients. To define the.
LIFEBLOOD THE Thrombosis CHARITY LIFEBLOOD THE Thrombosis CHARITY NICE Clinical Guideline 46.
VTE Prevention In Action Interactive Case Scenarios.
IVC filters what you need to know Sam Chakraverty Consultant Radiologist Ninewells Hospital Dundee, Scotland.
Chapter Seven Venous Disease Coalition Long-Term Management of VTE VTE Toolkit.
Risk Assessment for VTE. Which of the following best describes you?
Prophylaxis Diagnosis Treatment Venous Thromboembolism Management.
SANOFI-SYNTHELABOARIXTRA ® 1 ARIXTRA ® (fondaparinux sodium) in the prevention of venous thromboembolism after major knee surgery KA Bauer, BI Eriksson,
Surgical Care Improvement Project Prevention of Post-operative Venous Thromboembolism Team Membership Department of Surgery, Nursing, Pharmacy, CCE Confidential:
Peri-Operative anticoagulation /antiplatelet therapy A Shift in Paradigm BMHGT04/29/09.
Perioperative Medicine Beyond Cardiac Clearance Pamela Pride MD July 31, 2012 MUSC.
 Deep Vein Thrombosis Josh Vrona, Hunter Dolan, Erin McCann.
Oral Rivaroxaban Compared with Subcutaneous Enoxaparin for Extended Thromboprophylaxis After Total Hip Arthroplasty: The RECORD1 Trial Eriksson BI, Borris.
Oral, Direct Factor Xa Inhibition with Rivaroxaban for the Prevention of Venous Thromboembolism After Total Hip Replacement Eriksson BI, Borris L, Dahl.
Venous Thromboembolism (VTE) Prophylaxis at Cesarean Section Phillip N. Rauk, MD.
Antithrombotic Therapy for VTE: CHEST Guidelines 2016
Prevention of Venous Thromboembolism in Nonsurgical Patients Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Conclusions Results Methods Background Venous thrombo-embolism in patients undergoing neo- adjuvant chemotherapy and surgery for oesophago-gastric cancer.
Prevention of Venous Thromboembolism in Orthopedic Surgery Patients Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy.
Treatment of deep venous thrombosis and pulmonary embolism Anders Waage.
Prevention of Venous Thromboembolism in Nonsurgical Patients Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest.
Spotlight Case January 2006 An Ounce of Prevention.
Outpatient DVT assessment & treatment Daniel Gilada.
Introduction - Perioperative management of patients on warfarin or antiplatelet therapy involves assessing and balancing individual risks for thromboembolism.
By: Dr. Nalaka Gunawansa
The efficacy and safety of oral Rivaroxaban in patients with permanent inferior vena cava filter: a pilot case-control study Lobastov K., Barinov V.,
Ortho Warfarin Dosing Protocol
Prevention of Venous Thromboembolism in Orthopedic Surgery Patients
Owen N. Johnson, MD, David L
Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer 
Presentation transcript:

PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM LIFEBLOOD THE Thrombosis CHARITY PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM Nicolaides AN, Fareed J, Kakkar AK, Breddin HK, Goldhaber SZ, Hull R, Kakkar VV, Michiels JJ, Myers K, Samana M, Sasahara A, Kalodiki E.

Definition of risk categories – General surgery The definition of risk categories in general surgical patients using FUT and in hospital pulmonary embolism.* Category Frequency of calf vein thrombosis Frequency of proximal vein thrombosis Frequency of Fatal PE High Risk 40 – 80% 10 – 30% >1% Moderate Risk 10 – 40% 1 – 10% 0.1 – 1% Low Risk <10% <1% <0.1% *Although based on old studies the percentages shown in this table are still used to define the category of risk

Non-orthopaedic patients Risk categories – Non-orthopaedic patients Risk Category General Surgery Gynaecology Obstetrics High Major General Surgery, age>60 Major Gynaecological Surgery, age>60 History of DVT/PE Major General Surgery, age 40-60 & cancer or history of DVT/PE Major Gynaecological Surgery, age 40-60 & cancer or history of DVT/PE Thrombophilia Moderate Major General Surgery, age 40-60 without other risk factors** Major Gynaecological Surgery, age 40-60 Age >35 years Cesarean section Obesity Minor Surgery, age >60 Major Gynaecological Surgery, age<40 on oestrogen therapy Minor Surgery, age 40-60 with history of DVT/PE or on oestrogen therapy Low Major General Suregery, age <40 No other risk factors** Minor Gynaecological Surgery, age <40 without any other risk factors** Age <35 years Without any risk factors Minor Surgery, age 40-60 No other risk factors** Minor Gynaecological Surgery, age 40-60 without any other risk factors**

General surgery and vascular surgery – Moderate risk Moderate risk patients are those > 40 years undergoing major surgery for benign disease LDUH 5000U commenced preoperatively and continued twice or 3 times daily (Grade A) LMWH initiated and dosed according to manufacturers recommendations for moderate risk patients are recommended (Grade A) An alternative method, especially in patients at risk for or with active bleeding, is IPC with GEC compression used continuously until the patient is ambulant (Grade A)

General surgery and vascular surgery – high risk LDUH (5000U commenced 2h before operation and continued post-operatively 3 times a day (Grade A) LMWH initiated and dosed according to the manufacturer’s recommendations (Grade A) Both may be combined with mechanical methods (GEC or IPC) (Grade B) Fondaparinux (one study) is a (Grade B) recommendation

General surgery and vascular surgery Prophylactic subcutaneous LDUH, LMWH, or IPC with GEC are recommended only in patients with additional risk factors (Grade C)

Urological surgery IPC with GEC (Grade B) LDUH giving 5000U commenced 2h before operation and continued 3 times a day in the postoperative period (Grade A) LMWH initiated and dosed according to the manufacturer’s recommendations (Grade C)

Gynaecological surgery LMWH (Grade A) LDUH (5000IU 8 hourly) (Grade A) IPC (throughout hospital stay) (Grade B) LMWH or LDUH combined with IPC or GEC stockings provides optimal prophylaxis (Grade B)

Orthopaedic surgery – Hip replacement LMWH, fondaparinux, oral anticoagulant therapy, IPC or FIT combined with GEC (Grade A). LMWH or fondaparinux are preferred for in-hospital prevention. IPC or FIT combined with GEC stockings are an equivalent alternative to LMWH for those concerned about bleeding. Recombinant hirudin - used in HIT patients (Grade A) LMWH initiated either before or after operation (Grade A) Fondaparinux should be started 6-8 h after surgery Prophylaxis should be continued for 4-6 weeks with LMWH (Grade A) or fondaparinux (Grade C, extrapolation from hip fracture trial).

Orthopaedic surgery – Knee replacement LMWH or warfarin (less effective) (Grade A) Fondaparinux (Grade B) IPC or FIT plus GEC stockings are alternatives but more studies are needed (Grade B)

Orthopaedic surgery – Hip fracture LMWH, fondaparinux, adjusted dose VKA (INR: range 2-3), or LDUH (Grade A) IPC or FIT combined with GEC should be used when there are contraindications for pharmacological prophylaxis (Grade B) If surgery is likely to be delayed, prophylaxis should be initiated with LMWH or IPC or FIT plus GEC as close to the fracture as possible (Grade C)

Orthopaedic/trauma surgery LMWH starting as soon as bleeding risk is acceptable (Grade A) IPC in the presence of contraindications to LMWH (Grade B) and continued until full ambulation

Elective spine surgery IPC initiated before operation (Grade B) LMWH initiated after operation (Grade B) Duration: during hospitalisation (Grade C)

Spinal chord surgery IPC and GEC in combination with LMWH (Grade B) Initiation: IPC and GEC on admission LMWH when bleeding risk is acceptable (Grade C) Duration: LMWH and IPC for three months Continuation with GEC indefinitely (Grade C)

Neurosurgery IPC with or without graduated elastic compression stockings (Grade A) Addition of LMWH is associated with an increase of efficacy (Grade A)

Critical care LDUH or LMWH unless contraindicated (Grade A) For patients with contraindications to pharmacological prophylaxis, GEC stockings + IPC are an alternative (Grade C) In the absence of contraindications, combined mechanical plus pharmacologic prophylaxis (Grade C)

Cancer In surgical patients with cancer, LDUH (5000IU 8-hourly commenced prior to operation) or LMWH (Grade A) For patients at high risk for development of thromboembolic disease in the post-discharge period, prolonged thromboprophylaxis with enoxaparin 40 mg once daily for up to 4 weeks after operation (Grade B) In ambulant non-surgical cancer patients with advanced breast cancer receiving chemotherapy (see above): Use VKA to maintain an INR of between 1.3 and 1.9 (Grade B)

Inferior vena cava filters IVC filters are indicated in patients with PE or proximal DVT who have contraindications to anticoagulation or who have suffered recurrent PE while receiving adequate therapeutic anticoagulation (Grade B) Consider filter placement in patients with major trauma or pelvic fracture (Grade C) Indications for insertion and removal of retrievable IVC filters have not yet been established